| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0815 | avβ5 Inhibitor 12 | The first potent and selective αvβ5 integrin inhibitor |
|
| DCC0816 | Awd-12-281 | Novel PDE4 inhibitor |
|
| DCC0817 | Aws-i-169 | Novel specific inhibitor of HIV-1 entry through interaction with the Env spike by virtue of the incorporation of a guandinium group |
|
| DCC0818 | Ax1/mer-in-1 | Novel potent dual inhibitor of Ax1 and Mer |
|
| DCC0819 | Ax-10479 | Zn -dependent inhibitor of human plasma Lp-PLA2 |
|
| DCC0820 | Ax14373 | Highly specific JNK inhibitor #212121; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0 |
|
| DCC0821 | Ax15839 | Novel dual ERK5 and BRD4 inhibitor |
|
| DCC0822 | Ax15892 | Novel potent and selective ERK5 inhibitor |
|
| DCC0823 | Ax15910 | Novel potent dual ERK5 and BRD4 inhibitor |
|
| DCC0824 | Axl-in-13c | Novel highly potent and orally bioavailable Axl inhibitor |
|
| DCC0825 | Axt050 | Novel integrin-binding peptide, inhibiting hepatocyte growth factor (HGF) signaling through Met-integrin interactions, also being an antiangiogenic agent by reducing phosphorylation of VEGR2, IGFR, and PDGFR, stabilizing vessels by disrupting α5β1 signali |
|
| DCC0826 | ay-30068 | Cyclooxygenase Inhibitor; |
|
| DCC0827 | az1136 | Second Generation |
|
| DCC0828 | Az11760788 | Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist |
|
| DCC0829 | Az12048189 | Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist |
|
| DCC0830 | Az12080282 Dihydrochloride | Novel orally bioavailable inhibitor of Hedgehog signaling |
|
| DCC0831 | Az12099548 | Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist |
|
| DCC0832 | Az12489875-002 | Novel potent EphB4 inhibitor |
|
| DCC0833 | Az1366 | Novel tankyrase inhibitor, enhancing irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance |
|
| DCC0834 | Az-13767370 | Novel covalent ERK1/2 inhibitor |
|
| DCC0835 | Az7188 | Novel weak PAR2 antagonist |
|
| DCC0836 | Aza197 | Novel selective Cdc42 inhibitor, suppressing primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity |
|
| DCC0837 | aza-bodipy | Near-IR probe for detecting conformational changes of Aβ1-42 soluble oligomers in vitro |
|
| DCC0838 | azadirone | Inducer of Death Receptors and Sensitizer of Human Cancer Cells to TRAIL through a p53-Independent Mechanism |
|
| DCC0839 | Azalanstat | Inhibitor of hepatic cholesterol biosynthesis, inhibiting the cytochrome P450 enzyme lanosterol 14alpha-demethylase |
|
| DCC0840 | Aza-thip | Novel selective GABA-C antagonist |
|
| DCC0841 | Azd Cxcr2 Antagonist | Novel CXCR2 antagonist with 200 times improvement in solubility than AZD8309 |
|
| DCC0842 | Azd0328 | Selective alpha7 nicotinic receptor activator |
|
| DCC0843 | Azd1386 | Novel transient receptor potential vanilloid 1 (TRPV1) antagonist |
|
| DCC0844 | Azd1897 Featured | AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways. |
|
